Discontinued — last reported Q2 '22
Neulasta® (pegfilgrastim) — Total revenues
Products & Services · Total revenuesAmgen Neulasta® (pegfilgrastim) — Total revenues decreased by 10.9% to $310.00M in Q2 2022 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ3 2020
Last reportedQ2 2022
Rolls up toTotal Revenue
How to read this metric
An increase indicates strong net commercial performance and effective management of sales deductions, while a decrease signals potential erosion in net pricing or volume.
Detailed definition
This metric represents the total net revenue recognized for the specific therapeutic product line after all adjustments,...
Peer comparison
Comparable to net product revenue reported by peer biotechnology and pharmaceutical companies for individual drug assets.
Metric ID:
amgn_segment_neulasta_pegfilgrastim_total_revenuesHistorical Data
4 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | |
|---|---|---|---|---|
| Value | $486.00M | $415.00M | $348.00M | $310.00M |
| QoQ Change | — | -14.6% | -16.1% | -10.9% |
| YoY Change | — | — | — | -36.2% |
Range$310.00M – $486.00M
Avg YoY Growth-36.2%
Median YoY Growth-36.2%
Current Streak3+ quarters decline
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's neulasta® (pegfilgrastim) — total revenues?
- Amgen (AMGN) reported neulasta® (pegfilgrastim) — total revenues of $310.00M in Q2 2022.
- What does neulasta® (pegfilgrastim) — total revenues mean?
- The total net revenue earned from a specific therapeutic product after accounting for all sales deductions.